EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
75.30
-0.30 (-0.40%)
At close: Dec 5, 2025
-18.42%
Market Cap 22.76B
Revenue (ttm) 936.18M
Net Income (ttm) -705.76M
Shares Out 302.20M
EPS (ttm) -2.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 546,737
Average Volume 1,639,013
Open 75.60
Previous Close 75.60
Day's Range 74.10 - 76.90
52-Week Range 52.70 - 93.50
Beta 0.55
RSI 57.19
Earnings Date Nov 12, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.